LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting, with GFP

Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative ControlRead more

Catalog Number	Quantity
A32063	100 μL

Catalog number A32063

Price (CNY)

Quantity:

100 μL

Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome. This construct also expresses emGFP to provide a visual readout of successful transduction that can be used in determining Multiplicity of Infection (MOI).

For Research Use Only. Not for use in diagnostic procedures.

Specifications

Delivery TypeLentiviral

For Use With (Application)Genome Editing

Product LineLentiArray

Product TypegRNA

PromoterU6

Quantity100 μL

Shipping ConditionDry Ice

Control TypeNegative Control

FormatTube

RNAi TypegRNA

SpeciesHuman

Unit SizeEach

Contents & Storage

1 x 100 μL. Store (at -68°C to -85°C.)

Citations & References (1)

Citations & References

Abstract

A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.

Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T

Journal:Pediatr Blood Cancer

PubMed ID:28398638

Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More